OneAscent Financial Services LLC grew its holdings in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 126.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 8,020 shares of the company's stock after buying an additional 4,476 shares during the period. OneAscent Financial Services LLC's holdings in AstraZeneca were worth $584,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds also recently made changes to their positions in AZN. Capital International Investors raised its holdings in AstraZeneca by 1.9% during the fourth quarter. Capital International Investors now owns 37,507,159 shares of the company's stock worth $2,457,706,000 after purchasing an additional 686,008 shares in the last quarter. Bank of America Corp DE raised its holdings in AstraZeneca by 189.3% during the fourth quarter. Bank of America Corp DE now owns 24,026,966 shares of the company's stock worth $1,574,247,000 after purchasing an additional 15,722,197 shares in the last quarter. Franklin Resources Inc. raised its holdings in AstraZeneca by 1.9% during the fourth quarter. Franklin Resources Inc. now owns 19,480,569 shares of the company's stock worth $1,276,367,000 after purchasing an additional 357,894 shares in the last quarter. Sanders Capital LLC raised its holdings in AstraZeneca by 1.4% during the fourth quarter. Sanders Capital LLC now owns 15,186,692 shares of the company's stock worth $995,032,000 after purchasing an additional 212,301 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in AstraZeneca by 13.6% during the fourth quarter. Dimensional Fund Advisors LP now owns 5,322,388 shares of the company's stock worth $348,730,000 after purchasing an additional 636,537 shares in the last quarter. Institutional investors own 20.35% of the company's stock.
Analysts Set New Price Targets
Several research firms have recently commented on AZN. Berenberg Bank set a $97.00 price target on shares of AstraZeneca in a report on Wednesday, July 9th. BNP Paribas began coverage on shares of AstraZeneca in a report on Tuesday, April 15th. They set an "outperform" rating and a $75.00 price target on the stock. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat.com, AstraZeneca currently has a consensus rating of "Moderate Buy" and an average target price of $89.00.
Get Our Latest Stock Analysis on AstraZeneca
AstraZeneca Stock Down 1.5%
AstraZeneca stock traded down $1.09 during mid-day trading on Friday, reaching $72.60. The company's stock had a trading volume of 2,202,465 shares, compared to its average volume of 5,226,179. The company has a market capitalization of $225.14 billion, a price-to-earnings ratio of 29.15, a price-to-earnings-growth ratio of 1.34 and a beta of 0.37. AstraZeneca PLC has a 12 month low of $61.24 and a 12 month high of $87.68. The business's 50 day simple moving average is $71.08 and its 200 day simple moving average is $71.07. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.70 and a current ratio of 0.90.
AstraZeneca (NASDAQ:AZN - Get Free Report) last announced its earnings results on Tuesday, April 29th. The company reported $1.24 EPS for the quarter, topping the consensus estimate of $1.10 by $0.14. The business had revenue of $13.59 billion during the quarter, compared to the consensus estimate of $13.71 billion. AstraZeneca had a net margin of 14.14% and a return on equity of 33.14%. AstraZeneca's revenue was up 7.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.06 EPS. As a group, research analysts anticipate that AstraZeneca PLC will post 4.51 earnings per share for the current year.
About AstraZeneca
(
Free Report)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
See Also
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
